June 18: The Week in Cancer News
A study compares the benefits of fixed doses of immunotherapy compared to weight-based doses and more news of the week from the staff of Cancer Today magazine.
Progress Against Cancer
A study compares the benefits of fixed doses of immunotherapy compared to weight-based doses and more news of the week from the staff of Cancer Today magazine.
Scientists show that a form of DNA damage in colorectal cancer patients is associated with the consumption of red meat but not other foods or lifestyle factors.
The U.S. FDA has approved a molecularly targeted therapeutic to treat patients with advanced systemic mastocytosis. The U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic avapritinib (Ayvakit) to treat patients with...
They say age is just a number, but when it comes to cancer, getting older substantially increases your risk. Of the estimated 1.9 million cases of cancer diagnosed each year in the United States, approximately 80 percent are diagnosed in those over...
Triplet therapy shows promise for prostate cancer that was metastatic at diagnosis and more news of the week from the staff of Cancer Today magazine.
Most adults report inadequate knowledge of palliative care, according to a study published in the AACR journal Cancer Epidemiology, Biomarkers & Prevention.
A targeted therapy improves disease-free survival when given to people with certain hereditary mutations after breast cancer surgery, and more news of the week from Cancer Today.
The U.S. FDA has granted accelerated approval to the first KRAS inhibitor, along with two companion diagnostics, for certain patients with KRAS-mutated lung cancer. The U.S. Food and Drug Administration (FDA) granted accelerated approval...
A study finds that many people with solid tumors mount an antibody response following COVID-19 vaccination, and more news of the week from Cancer Today.
The FDA has granted accelerated approval to a molecularly targeted therapeutic along with a companion diagnostic to treat certain patients with cholangiocarcinoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More